semaglutide bad for you Comparative safety and side effects of and tirzepatide: Implications clinical decision-making in obesity management Common And Rare Side Effects

Dose titration and its impact Most GLP-1 protocols involve gradual dose increases during months two and three

By contrast, among specialist doctors the newer obesity agents are much more front-of-mind: over three quarters of specialists surveyed first mentioned a GLP-1 agonist in response to the question above

So I think it is very, very promising, but I would not, as an oncologist, consider the data at this point definitive

GLP-1 receptor agonists are emerging as a safe and efficient treatment option for children with obesity or metabolic syndrome, 17,18 and some studies suggest that baseline levels of incretins might even be able to predict individual responses, 19 further understating a need to qualify reference intervals

Other than that, many Aetna plans do not cover Zepbound for weight loss, including Aetna Advanced Control and Aetna Standard Control plans

Tirzepatide acts on two hormone pathways (GLP-1 and GIP) rather than just one which might help explain why tirzepatide has produced greater average weight loss in some studies